Capt. Chaos (@AndrewDigby3) header
Capt. Chaos (@AndrewDigby3) profile picture

It's all about mindset. Shares are stepping stones to your goal. Looking for the next bagger. Tweets are my opinion only. DYOR

Joined August 2014
Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)Photo by Capt. Chaos (@AndrewDigby3)
Replying to @AndrewDigby3
Avacta is in a different universe, as they're going after the biggest selling ADC of all time with their "unique industry-leading technology platform".
1
2
22
582
Replying to @PolitlcsUK
Savvy Squirrel says check out @avacta
2
19
431
Capt. Chaos retweeted
Not only did PM Starmer claim credit for the fall in inflation and the stock market rally in his interview with BBC'S Laura Kuenssberg, but he also had the temerity to try and hang the banking crisis on the previous government, when it happened under Labour's rule! Staggering!
93
475
24
2,393
35,210
Looking at the posters, ok Avacta haven’t yet 100% found a cure for cancer but imo it’s fucking close and our sp can’t even touch 40p (yet) at some point the penny will drop but it may be too late for retail. Wake up FFS !!! #AVCT
1
1
1
20
3,224
As far as pre|CISION® enabled drug conjugates are concerned it would appear that one can never have too much of a good thing, with not one but two new assets. Let us see how the bears cope with this new #AVCT development. @ZaksTradersCafe
7
14
3,253
Capt. Chaos retweeted
This is River. She loves watching the sunrise. Knows that no matter how dark the night gets, the sun will always be there in the morning.
207
1,685
103
20,022
453,733
Capt. Chaos retweeted
Replying to @Cumulus51896691
1
25
1,959
Capt. Chaos retweeted
#AVCT Imagine a 60 year old male. It could be you. Your husband. Your dad. The fun uncle you always loved seeing as a child. In early 2021, he felt a lump behind his right knee. An ice pack didn’t help. Ibuprofen and physio exercises didn’t help. Finally he went to the doctor. Biopsy. Grade 3 undifferentiated pleomorphic sarcoma, a rare type of cancer. Three months of radiotherapy followed by surgery. Viable tumour cells in under 10% of tumour volume - all seems well by September 2021. By March 2022, he’s diagnosed with severe Stage 4 cancer which has spread to the membrane around his lungs. By June 2022 options are running out, and he’s put on an early trial for a new combination therapy (Etigilimab + Nivolumab) for 6 months. He has a 41% chance of grade 3+ treatment-emergent adverse effects which could be life threatening in themselves. The disease continues to progress. He then enrolls in the @avacta AVA6000 trial at the beginning of 2023. Over the course of 11 months between February 2023 and January 2024, he has a near complete resolution of multiple metastatic lesions in the pleura (a -74% in the diameter of the lesions). See scans below. During his time on AVA6000 (and last we heard he was still on drug 14 months later), his chances of developing neutropenia dropped by two-thirds compared to naked doxorubicin, and chances of febrile neutropenia dropped to 0%. Importantly, quality of life has been greatly improved. AVA6000 boasts a 50% reduction in patients experiencing nausea, an over 50% reduction in patients experiencing decreased appetite, and the chances of experiencing pain or constipation decreasing 7 fold. Bear in mind we are seeing this efficacy during a phase 1a safety and tolerability study. Bear in mind this is only one patient - there are many others. The data can only continue to get better. In the near term, I suspect the precision platform will be linked to other drugs which are designed to have greater efficacy against other types of cancers for which doxorubicin is not the gold standard. This pipeline is due to be revealed by the end of the year. Are Avacta worried cancers such as pancreatic, colorectal and biliary tract are only FAPmid not FAPhigh? No chance. The attached graph shows the platform works just as well in both circumstances. This is real world stuff affecting real people just like me and you - already making a huge difference to treatment outcomes as well as quality of life during treatment. Would you want yourself or your loved one on AVA6000 as opposed to standard doxorubicin? I would. I eagerly await the data from the 2-weekly dosing schedule which are to be presented at @myESMO before we move into the phase 1b expansion cohorts later in the year. Thoughts welcome, let’s continue to strive for progress. @annals_Oncology @OncoAlert @ACSNews @EORTC @brunolarvol @MakisMD @CD_AACR @DrChoueiri @vivekSubbiah @Liz_ORiordan @JTrentMDPhD @Alegronchi @herbloong @MBCadvocate @Winette_vdGraaf @pawel_sobczuk @theNCI @CR_UK @VriesElisabeth @TimGreten @jsoriamd @PTarantinoMD @ElenaGarralda @NCIEytanRuppin @NEJM @Cancer_cell @NatureCancer @RonDePinho @Simocristea @DCalleMD @breelynwilkyMD @DrLaraDavis @sarcomapatients @t0mclark3 @barneycalman @rebeccasmt @andrewgregory @eleanorhayward @richardhorton1 @BBCHughPym @HSJEditor @ShaunLintern @Nicktriggle @dennis_campbell @Kamranabbasi
8
45
6
221
19,497
16
58
6
867
69,939
RT @Share_Talk: Quietly in a stealth way #AVCT broke the distance line from back in July, we have come back from the 73p level @ZaksTraders…
This quoted post is unavailable.
This is a good read - shorturl.at/41jsz Once you have medicated your way past the frustration of the Q1 placing, you see the abundance of opportunity before us. “Biologics and small molecules continue to attract the most popular investments and licensing deals.” #AVCT
3
36
3,767
Replying to @MorbidKnowledge
The man of the year.. Respect 🙏 xitter.gq/YourTwitFace3/status/1…
61
162
21
2,158
471,324
Last I will say on this but if we ALL #AVCT holders put a high sell-order on our stocks, I’m pretty sure this cannot be circumvented by inter-broker securities lending. For me as a Halifax SD customer, the cost is £2. PI’s should no longer be cannon fodder for II’s, HF’s etc.
8
7
23
6,153
Capt. Chaos retweeted
Only 135% to go and #AVCT will sit at the level it did before the trial had even begun 940 days ago. Meanwhile, 40 patients have been dosed, deepening tumour shrinkage is being observed and the drug is safe. Market awarding zero recognition for what has been achieved here.
1
3
31
4,134
2/ (“…and lots are saying they want it…”) i.e. the technological ability to target the stroma as well as cancer cells. Roll on news in the near term on how the tech is hopefully transforming quality of life in C6, 7 and Q2W trial patients. #AVCT
1
1
16
2,051
Encouraged about subtle/ important change in how @avacta #AVCT conveys its key technology to the world. Peptide Drug Conjugate-PDC juxtaposes against Antibody Drug Conjugates. Our MOA is very special. As EF said, it’s cool because it hits stroma; not only cancer cells. 1/
1
2
23
2,863
Capt. Chaos retweeted
Odd week at #AVCT. I still can’t quite believe management would entertain a placing at these levels but the lack of RNS continues to confound. If there is a placing at or around this level, I’d like to know the following: (1) Heights were placed by STFL for 95p in October 2022. That’s over 14 months ago and before the Company had unequivocally proven “preCISON works”. Please can you explain why the Company is being forced to raise below the level achieved 15 months ago? (2) Why were shareholders told by the CEO that the company had lots of “optionality” and not to worry about funding? (3) Why was this message repeated in late December 2023 on various occasions? (4) Does the Board believe <95p undervalues AVCT? If so, why was said placing entertained? How does the Board believe the viability of preCISION has changed since they refused the Accelerate placing (85p) in June 2023? (5) If there is a placing <95p, will the CEO and CFO forgo their options package (1.5m each) awarded in September 2023? (6) If the CEO and CFO will not forgo their combined 3m options package, can shareholders have an explanation as to whether RemCo believe a funding event <95p would mean the vesting criteria is met for the award? (7) Did the mgmt of AVCT receive any offers for funding north of 95p over the last 12 months? Has mgmt of AVCT ever received an offer specifically to remove the CLN via a separate funding package? (8) Why did the Board opt for dilution of shareholders over a sale of Diagnostics? (9) When is the first Affimer powered Dx device estimated to be launched? (10) Why was there no challenge at Board level when these acquisitions were proposed? (11) Why was a second Dx acquisition made (Coris) when AVA3996 had still not received IND? Why was Dx prioritised over AVA3996? (12) How many institutions have STFL brought on board since their appointment? (13) Given the leakage the Company saw with its last failed placing in June 2023, what lessons were learnt from that exercise and how did the Board seek to prevent them on this occasion? (14) Why does the Board believe a 46.58% decline in market cap over the past year has occurred when the AIM all share index is down 12.3%? Should a placing occur at @avacta over the next fortnight and you would like answers to the above, please RETWEET these questions.
19
13
63
11,417